ICU MED INC's ticker is ICUI and the CUSIP is 44930G107. A total of 272 filers reported holding ICU MED INC in Q3 2021. The put-call ratio across all filers is 1.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,724,170 | -36.1% | 190,943 | -4.3% | 0.01% | -28.6% |
| Q2 2023 | $35,569,932 | +5.8% | 199,618 | -2.1% | 0.01% | 0.0% |
| Q1 2023 | $33,622,591 | +4.4% | 203,823 | -0.3% | 0.01% | 0.0% |
| Q4 2022 | $32,198,361 | +5.5% | 204,460 | +0.9% | 0.01% | 0.0% |
| Q3 2022 | $30,524,000 | -7.6% | 202,680 | +0.9% | 0.01% | -12.5% |
| Q2 2022 | $33,021,000 | -27.4% | 200,877 | -1.7% | 0.01% | -11.1% |
| Q1 2022 | $45,501,000 | -7.9% | 204,368 | -1.8% | 0.01% | 0.0% |
| Q4 2021 | $49,383,000 | +0.2% | 208,073 | -1.5% | 0.01% | -10.0% |
| Q3 2021 | $49,302,000 | +21.7% | 211,253 | +7.3% | 0.01% | +25.0% |
| Q2 2021 | $40,517,000 | +1.1% | 196,880 | +0.9% | 0.01% | 0.0% |
| Q1 2021 | $40,081,000 | -6.5% | 195,100 | -2.3% | 0.01% | -11.1% |
| Q4 2020 | $42,845,000 | +16.9% | 199,751 | -0.4% | 0.01% | 0.0% |
| Q3 2020 | $36,666,000 | -0.8% | 200,627 | +0.1% | 0.01% | -10.0% |
| Q2 2020 | $36,948,000 | -6.2% | 200,474 | +2.7% | 0.01% | -23.1% |
| Q1 2020 | $39,387,000 | +5.4% | 195,207 | -2.2% | 0.01% | +30.0% |
| Q4 2019 | $37,367,000 | +22.2% | 199,692 | +4.2% | 0.01% | +25.0% |
| Q3 2019 | $30,591,000 | -33.5% | 191,681 | +5.0% | 0.01% | -38.5% |
| Q2 2019 | $45,987,000 | +3.5% | 182,561 | -1.6% | 0.01% | +8.3% |
| Q1 2019 | $44,413,000 | -6.3% | 185,567 | -10.1% | 0.01% | -20.0% |
| Q4 2018 | $47,399,000 | -12.7% | 206,412 | +7.5% | 0.02% | +7.1% |
| Q3 2018 | $54,275,000 | +6.5% | 191,956 | +10.6% | 0.01% | 0.0% |
| Q2 2018 | $50,947,000 | +14.5% | 173,491 | -1.6% | 0.01% | +16.7% |
| Q1 2018 | $44,505,000 | +13.4% | 176,328 | -3.0% | 0.01% | +20.0% |
| Q4 2017 | $39,262,000 | +15.6% | 181,771 | -0.5% | 0.01% | +11.1% |
| Q3 2017 | $33,957,000 | +6.3% | 182,715 | -1.3% | 0.01% | 0.0% |
| Q2 2017 | $31,938,000 | +10.6% | 185,148 | -2.1% | 0.01% | +12.5% |
| Q1 2017 | $28,882,000 | -30.4% | 189,147 | -32.9% | 0.01% | -33.3% |
| Q4 2016 | $41,518,000 | +9.7% | 281,768 | -5.9% | 0.01% | +9.1% |
| Q3 2016 | $37,851,000 | +10.5% | 299,502 | -1.4% | 0.01% | +10.0% |
| Q2 2016 | $34,242,000 | +3.8% | 303,687 | -4.2% | 0.01% | 0.0% |
| Q1 2016 | $32,986,000 | +30.8% | 316,862 | +41.7% | 0.01% | +25.0% |
| Q4 2015 | $25,220,000 | +32.0% | 223,620 | +28.1% | 0.01% | +33.3% |
| Q3 2015 | $19,113,000 | +37.3% | 174,551 | +19.9% | 0.01% | +50.0% |
| Q2 2015 | $13,924,000 | +6.3% | 145,551 | +3.5% | 0.00% | +33.3% |
| Q1 2015 | $13,097,000 | +15.1% | 140,607 | +1.2% | 0.00% | 0.0% |
| Q4 2014 | $11,377,000 | +23.0% | 138,914 | -3.6% | 0.00% | 0.0% |
| Q3 2014 | $9,252,000 | -44.6% | 144,164 | -47.5% | 0.00% | +50.0% |
| Q2 2014 | $16,712,000 | -26.9% | 274,798 | -28.0% | 0.00% | -66.7% |
| Q1 2014 | $22,868,000 | -13.9% | 381,903 | -8.3% | 0.01% | -14.3% |
| Q4 2013 | $26,546,000 | -47.5% | 416,670 | -44.1% | 0.01% | -12.5% |
| Q3 2013 | $50,604,000 | +65.2% | 744,938 | +75.2% | 0.01% | -20.0% |
| Q2 2013 | $30,639,000 | – | 425,190 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EVR Research LP | 22,000 | $4,719,000 | 3.86% |
| NUANCE INVESTMENTS, LLC | 901,483 | $193,359,000 | 3.73% |
| Nitorum Capital, L.P. | 417,241 | $89,494,000 | 3.46% |
| Tamarack Advisers, LP | 73,000 | $15,452,000 | 3.22% |
| PFM Health Sciences, LP | 267,817 | $57,444,000 | 2.02% |
| KIRR MARBACH & CO LLC /IN/ | 22,222 | $4,766,000 | 1.49% |
| PURA VIDA INVESTMENTS, LLC | 174,399 | $37,407,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,584 | $554,000 | 0.88% |
| Findlay Park Partners LLP | 528,825 | $113,428,000 | 0.79% |
| Altium Capital Management LP | 9,321 | $1,999,000 | 0.75% |